TY - JOUR
T1 - The updated European Consensus 2009 on the use of Botulinum toxin for children with cerebral palsy
AU - Heinen, Florian
AU - Desloovere, Kaat
AU - Schroeder, A. Sebastian
AU - Berweck, Steffen
AU - Borggraefe, Ingo
AU - van Campenhout, Anya
AU - Andersen, Guro L.
AU - Aydin, Resa
AU - Becher, Jules G.
AU - Bernert, Günther
AU - Caballero, Ignacio Martinez
AU - Carr, Lucinda
AU - Valayer, Emmanuelle Chaleat
AU - Desiato, Maria Teresa
AU - Fairhurst, Charlie
AU - Filipetti, Paul
AU - Hassink, Ralph Ingo
AU - Hustedt, Ulf
AU - Jozwiak, Marek
AU - Kocer, Serdar Ibrahim
AU - Kolanowski, Elisabeth
AU - Krägeloh-Mann, Ingeborg
AU - Şehim Kutlay, Kutlay
AU - Mäenpää, Helena
AU - Mall, Volker
AU - McArthur, Paul
AU - Morel, Edith
AU - Papavassiliou, Antigone
AU - Pascual-Pascual, Ignacio
AU - Pedersen, Søren Anker
AU - Plasschaert, Frank S.
AU - Irene van der Ploeg, van der Ploeg
AU - Remy-Neris, Olivier
AU - Renders, Anne
AU - Di Rosa, Guiseppe
AU - Steinlin, Maja
AU - Tedroff, Kristina
AU - Valls, Joan Vidal
AU - Viehweger, Elke
AU - Molenaers, Guy
N1 - Funding Information:
Dr. Heinen and Dr. Berweck have received speaker's honoraria, research support and travel grants from manufacturers of the different BoNT preparations available (Allergan, Germany, IPSEN, Germany, Merz Pharmaceuticals, Germany). Dr. Schroeder reports having received lecture fees and travel grants from Allergan, Germany.
PY - 2010/1
Y1 - 2010/1
N2 - An interdisciplinary European group of clinical experts in the field of movement disorders and experienced Botulinum toxin users has updated the consensus for the use of Botulinum toxin in the treatment of children with cerebral palsy (CP). A problem-orientated approach was used focussing on both published and practice-based evidence. In part I of the consensus the authors have tabulated the supporting evidence to produce a concise but comprehensive information base, pooling data and experience from 36 institutions in 9 European countries which involves more than 10,000 patients and over 45,000 treatment sessions during a period of more than 280 treatment years. In part II of the consensus the Gross Motor Function Measure (GMFM) and Gross Motor Function Classification System (GMFCS) based Motor Development Curves have been expanded to provide a graphical framework on how to treat the motor disorders in children with CP. This graph is named "CPGraph Treatment Modalities - Gross Motor Function" and is intended to facilitate communication between parents, therapists and medical doctors concerning (1) achievable motor function, (2) realistic goal-setting and (3) treatment perspectives for children with CP. The updated European consensus 2009 summarises the current understanding regarding an integrated, multidisciplinary treatment approach using Botulinum toxin for the treatment of children with CP.
AB - An interdisciplinary European group of clinical experts in the field of movement disorders and experienced Botulinum toxin users has updated the consensus for the use of Botulinum toxin in the treatment of children with cerebral palsy (CP). A problem-orientated approach was used focussing on both published and practice-based evidence. In part I of the consensus the authors have tabulated the supporting evidence to produce a concise but comprehensive information base, pooling data and experience from 36 institutions in 9 European countries which involves more than 10,000 patients and over 45,000 treatment sessions during a period of more than 280 treatment years. In part II of the consensus the Gross Motor Function Measure (GMFM) and Gross Motor Function Classification System (GMFCS) based Motor Development Curves have been expanded to provide a graphical framework on how to treat the motor disorders in children with CP. This graph is named "CPGraph Treatment Modalities - Gross Motor Function" and is intended to facilitate communication between parents, therapists and medical doctors concerning (1) achievable motor function, (2) realistic goal-setting and (3) treatment perspectives for children with CP. The updated European consensus 2009 summarises the current understanding regarding an integrated, multidisciplinary treatment approach using Botulinum toxin for the treatment of children with CP.
KW - Botulinum toxin
KW - Cerebral palsy
UR - https://www.scopus.com/pages/publications/71949092112
U2 - 10.1016/j.ejpn.2009.09.005
DO - 10.1016/j.ejpn.2009.09.005
M3 - Review article
C2 - 19914110
AN - SCOPUS:71949092112
SN - 1090-3798
VL - 14
SP - 45
EP - 66
JO - European Journal of Paediatric Neurology
JF - European Journal of Paediatric Neurology
IS - 1
ER -